Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Zepzelca (lurbinectedin)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Boryung Group, Jazz, Key Oncologics, Luye Group, PharmaMar, Specialised Therap

Drug class:

Alkylating agent, Apoptosis stimulant, RNA polymerase inhibitor

Related drugs:

‹

alpha-tocopheroloxyacetic acid (0)

darinaparsin (0)

elemene injection (0)

BS-HH-002.SA (0)

piceatannol (0)

cyclophosphamide (66)

trabectedin (24)

carmustine (14)

chlorambucil (7)

melphalan flufenamide (7)

temozolomide gel (7)

procarbazine hydrochloride (4)

bendamustine RTD (2)

fotemustine (2)

FGX15-147-based ADC (1)

bendamustine rapid infusion (0)

ranimustine (0)

carmustine implant (0)

altretamine (0)

mechlorethamine (0)

pegylated liposomal mitomycin-c prodrug (0)

mechlorethamine gel (0)

captisol-enabled melphalan (0)

cyclophosphamide intravenous (0)

arsenic trioxide (6)

omacetaxine mepesuccinate (4)

quaratusugene ozeplasmid (3)

teserpaturev (1)

ABI-1968 topical cream (0)

autologous γδ T lymphocytes (0)

84AA-API 14AA (0)

alpha-tocopheroloxyacetic acid (0)

darinaparsin (0)

elemene injection (0)

BS-HH-002.SA (0)

piceatannol (0)

›

No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	lurbinectedin Sensitive: A1 - Approval lurbinectedin Sensitive : A1	lurbinectedin Sensitive: A1 - Approval lurbinectedin Sensitive : A1
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	lurbinectedin Sensitive: A2 - Guideline lurbinectedin Sensitive : A2	lurbinectedin Sensitive: A2 - Guideline lurbinectedin Sensitive : A2
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	lurbinectedin Sensitive: C2 – Inclusion Criteria lurbinectedin Sensitive : C2	lurbinectedin Sensitive: C2 – Inclusion Criteria lurbinectedin Sensitive : C2
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	lurbinectedin Sensitive: C2 – Inclusion Criteria lurbinectedin Sensitive : C2	lurbinectedin Sensitive: C2 – Inclusion Criteria lurbinectedin Sensitive : C2
SLFN11 overexpression	Small Cell Lung Cancer	SLFN11 overexpression	Small Cell Lung Cancer	lurbinectedin Sensitive: D – Preclinical lurbinectedin Sensitive : D	lurbinectedin Sensitive: D – Preclinical lurbinectedin Sensitive : D
SLFN11 underexpression	Small Cell Lung Cancer	SLFN11 underexpression	Small Cell Lung Cancer	M6620 + lurbinectedin Sensitive: D – Preclinical M6620 + lurbinectedin Sensitive : D	M6620 + lurbinectedin Sensitive: D – Preclinical M6620 + lurbinectedin Sensitive : D
SLFN11 underexpression	Small Cell Lung Cancer	SLFN11 underexpression	Small Cell Lung Cancer	AZD6738 + lurbinectedin Sensitive: D – Preclinical AZD6738 + lurbinectedin Sensitive : D	AZD6738 + lurbinectedin Sensitive: D – Preclinical AZD6738 + lurbinectedin Sensitive : D
POU2F3 overexpression	Small Cell Lung Cancer	POU2F3 overexpression	Small Cell Lung Cancer	lurbinectedin Sensitive: D – Preclinical lurbinectedin Sensitive : D	lurbinectedin Sensitive: D – Preclinical lurbinectedin Sensitive : D
ERCC5 overexpression	Small Cell Lung Cancer	ERCC5 overexpression	Small Cell Lung Cancer	M6620 + lurbinectedin Sensitive: D – Preclinical M6620 + lurbinectedin Sensitive : D	M6620 + lurbinectedin Sensitive: D – Preclinical M6620 + lurbinectedin Sensitive : D
SLFN11 overexpression	Small Cell Lung Cancer	SLFN11 overexpression	Small Cell Lung Cancer	M6620 + lurbinectedin Sensitive: D – Preclinical M6620 + lurbinectedin Sensitive : D	M6620 + lurbinectedin Sensitive: D – Preclinical M6620 + lurbinectedin Sensitive : D
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	lurbinectedin Sensitive: D – Preclinical lurbinectedin Sensitive : D	lurbinectedin Sensitive: D – Preclinical lurbinectedin Sensitive : D